Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Coast to Coast for Cures – reflections on the ride of a lifetime

Breakthrough T1D Canada Board Member Matt Varey rode across Canada in support of type 1 diabetes (T1D) research

On May 3, Matt Varey, a longtime volunteer with Breakthrough T1D Canada (formerly JDRF) and current Co-Chair of the Breakthrough T1D International Board, began a 61 day, 7400km+ journey to cycle across Canada. At 61, Matt had recently retired from a long career with RBC and though he has no personal connection to type 1 diabetes, he has become a passionate advocate over the past 20 years for Canadians living with T1D. Matt’s goal was to raise $500,000 and he surpassed it, raising over $535,000 and counting.

Matt’s journey saw all four seasons of weather as he crossed the country, and he endured excruciatingly long days, injury, and with no rest stops, truly tested his own mental and physical endurance on the road. Travelling with Matt was his wife, Andrea, and their dog, Handel, and they were joined by several of Matt’s lifelong best friends along the way. Matt’s friends Kirk, Stew and Steve had his back from the first day Matt and AJ decided on this journey, and they dropped everything to join him on the road; the mark of true friendship. Their team was small but what they’ve accomplished for the type 1 diabetes community has been extraordinary.

On July 2, Matt finished his ride in Halifax by dipping his tire in the Atlantic Ocean, book-ending a similar dip on May 3 in Victoria in the Pacific Ocean at the start of his journey. It was the emotional culmination of an audacious but incredibly meaningful journey.

Breakthrough T1D Canada spoke with Matt following his Ride to discuss his amazing once-in-a-lifetime personal journey and achievement in support of critical T1D research and support for the T1D community.

Breakthrough T1D Canada: How are you feeling today?

Matt: I feel tremendous. And let me tell you that the reason I’m feeling tremendous is because AJ and I were blown away by the absolute kindness, generosity, and sheer humility of society. That’s what I think about every day. The generosity we experienced everywhere we went across this country. We were both just so incredibly touched by how much people truly cared about the mission and the purpose. So, that’s how I feel.

Breakthrough T1D Canada: What surprised you the most?

Matt: Oh wow, several things surprised me, and I will share them in no particular order. Mother Nature surprised me. She thew so many different environments at us, you just had to have this ability to adapt and not get upset. I was continually surprised by how she can change the environment so quickly, and so sharply. This surprised both my wife and me.

Mother Nature can be relentless but at the same time, she can create serenity in the mornings, and at night. Really, the whole natural aspect of the journey, from the birds waking me up in the morning to the birds putting me to bed at night. The noises, the sound of the wind through the trees.

And then as I rode through tougher terrain, and through the areas heavily impacted by forest fires, it seemed to me that the trees were crying, We saw Mother Nature angry with the forest fires. You just saw the forest was sad, tired and dry. And when we saw the smoke, I thought it was Mother Nature crying. And that was unexpected but moving in its own way.

I thought I understood before, but I was in fact still surprised also by the beauty and diversity of Mother Nature, by the sheer beauty of Canada that I had not experienced until this ride. Cycling through just some of the most beautiful places on earth, Northern Lake Superior, the sheer beauty of the Saint John River Valley, the beautiful white churches in southern Quebec, your senses come alive when you’re on the bike, I didn’t have modern day distractions. So, all my senses were on high alert, I could truly smell a farmer’s field, or the scent of fresh cut grass.

And then on the other side of that – I was surprised by how noisy society is. The constant noise of being so close to cars, transport trucks, so close to you all day. You could sense they were coming closer before they did or feel the respect and distance they might give because I was on a bike. You pick up societal noises so much more.

Another thing that AJ and I were surprised and touched by was the sheer trust that human beings give you despite not knowing you. How decent is that? You get a flat tire, there’s no bike shop in a rural community, just a truck stop – and they don’t fix bike tires. Except they do! They see me, a person out on the road needing help, and they jump to give that help.

We were in Lake Louise, Alberta, it was two degrees, and I was cycling through rain and sleet, and my chain broke. And people, they just dropped everything to help. As soon as we mentioned the purposeful journey we were on, people trust you immensely, and want to be a hand on your back, they want to be someone who uplifts and supports you.

I was doing my washing in a laundromat, and a man saw my shirt and asked me what it meant, what I was doing? After telling him, he reached into this pocket to take out $50 and give it to me with the request that I do good things with it. I was so moved by the enormous trust that people give you.

The other surprise was RBC. I always knew it was a purposeful organization; I knew it had a cultural heart and soul, but this was a whole new level. My former colleagues and friends, and the grassroots support they provided, and I’m retired – I don’t work there anymore! But it was just a steamroll of giving from coast to coast.

Nobody said they were too busy for the activation events (pitstops) they came out on in the middle of the day; they came out on weekends. They gave their time and energy in support of this purposeful journey, and that helped drive me. RBC proved to be a deeply human organization, all these folks had a choice, to go about their life, go about their job – they interrupted both to come out and show support.

And of course, we were surprised by the sheer emotions, and how much it impacted us both. Not everyone knows the details of that.

The Breakthrough T1D ambassadors, each one imprinted on me in a different way. AJ and I, we know that if you had T1D, you don’t have a choice but to be courageous. You must be every day. But what surprised us was their quiet determination, their poise, and how they move forward with positivity. How they truly believe that tomorrow is going to be better than today. It took our understanding about living with T1D and what that entails to a whole new level. And that too helped drive both of us every day.

Breakthrough T1D Canada: What did you learn on your journey?

Matt: You learn a tremendous amount about your body, both physically and mentally. It tells you physically, when you can power through, that you have more fuel in your tank. You know before you even get on the road when you are going to have a tough day. Your body gets mad at you. It doesn’t want to do the same thing for 60 straight days. It surprised me that my body gave me two million pedal strokes, but it got mad at me at the same time. It most definitely was angry at me more than once. But I did learn this – you always have more fuel in your tank than you think.

I learned that I needed to just really focus on the positives. When I was so tired and didn’t want to go another kilometre. I would look down at my arm and at the Breakthrough T1D tattoo I got before starting this journey, and I would think to myself ‘I don’t want to do this, but yes I can’. My mind and body taught me so much for so many varied reasons.

Breakthrough T1D Canada: How do you feel about your connection to the T1D community now?

The first word that intuitively comes to mind is that they are even more courageous than I realized over my two decades with this organization. The organizational heart of Breakthrough T1D, I always say that a mind can be convinced, but a heart needs to be won. And when you have both, like Breakthrough T1D does – you can do anything. It became even more apparent what a people-led and purposeful organization this is. And then getting to meet Ambassadors, parents of children with T1D, or even people my age who have been living with this disease for decades. It gave me confidence, and it gave me hope.

Listening to Jessica Diniz (President and CEO of Breakthrough T1D Canada), Aaron Kowalski (President and CEO of Breakthrough T1D International) or board members – it just reinforced for both me and AJ that Breakthrough T1D is a family. It’s not simply an organization, it’s a family and everyone is connected because they are traveling on the same journey. Despite the difficulties of my specific journey, they came together with these family-like bonds. There are very few true bonds left in business. And Breakthrough T1D is a family from coast to coast at every level.

And we want to recognize as well the tremendous support of Katie, Lynne, Dennis and everyone at Breakthrough T1D Canada who worked tirelessly on this journey too. We have never known such a culture of support as the one at Breakthrough T1D.

Breakthrough T1D Canada: Any final thoughts?

Matt: My wife AJ is the most remarkable person that I have ever known. And what she did – for this journey, for me, was the most selfless act that I have ever known or seen or will ever experience. Without her, there was absolutely not a hope that I – but I mean we – could have done this journey. I love her dearly, but this took it to a whole new level.

Out of everything, I will remember what she did more than anything else. Life is about memories, and what I’m going to be left with are memories for life that I will never forget, and that have changed me.

This journey changed me. It made me look at things even more positively. We live in such a remarkable country, which is so kind and so beautiful in its soul. I could only experience that beauty by seeing it replicated over and over – in small towns, in big cities, in bike shops, pastry shops, restaurants, anywhere we went. The circulatory system of this country just pumps decency everywhere. I feel blessed to have experienced it and my gratitude can’t be properly expressed.

It’s also amazing how you can connect with society through social media. I had never used it before this event. But throughout my ride, I would read the comments on LinkedIn, especially when I was tired and didn’t want to get up, didn’t want to get back on my bike. But the humans on the other end would help keep me going. I never knew I could feel humanity that way through a computer. So, thank you to everyone who left me a note and helped fuel my commitment to this purposeful journey. You did more for me than you will ever realize.

I’m also so appreciative that Breakthrough T1D gave me and AJ the opportunity to do this, and I feel incredibly blessed and just so grateful to everyone at this organization, to the people I met out on the road, to the volunteers, to the ambassadors and to everyone who supported us along the way. Thank you. From the bottom of my heart – thank you.

***

Breakthrough T1D once again extends its enormous gratitude to Matt and AJ, to the volunteers, staff and everyone at RBC who contributed to the incredible success of Coast to Coast for Cures.

To learn more: https://breakthrought1d.akaraisin.com/ui/CoastToCoastForCures

Annual American Diabetes Association Conference provides updates in all fields of type 1 diabetes research

The American Diabetes Association’s 85th Scientific Sessions were held from June 21- 24th, 2025. The research presented at ADA covers all areas of type 1 diabetes (T1D) developments, including devices, adjunct therapies and the latest in cell therapies.

Updates in cell therapies research

Dr. Andrew Pepper (Edmonton) presented on vascularization strategies to increase the survival and functionality of transplanted islets. The implantation of a biomaterial under the skin will trigger the immune system and initiate a foreign body reaction, which results in the formation of blood vessels and structural components around the foreign object. Removal of the object leaves a hollow pre-vascularized core suitable for islet transplantation. This process can be optimized by using a biodegradable material, so no removal is required, and by the addition of “accessory cells” such as stem cells that are programmed to form blood vessels to help maintain a vascularized environment for islets.

Most Pressing Challenge in Cell Therapy: When the panel of experts was asked about the biggest hurdle to bring cell therapies to people, the answer was unanimous – removing immunosuppressants while maintaining efficacy and safety. 

This is a primary area of focus for Breakthrough T1D and the aim of many ongoing projects by Canadian researchers with Breakthrough T1D funding. One example is work led by Dr. Andras Nagy (Toronto) and Dr. Tim Kieffer (Vancouver) presented at ADA:

Dr. Nagy’s lab has identified eight immunomodulatory genes that, when modified, can cause transplanted cells to be ‘cloaked’ and evade immune rejection. The work presented at ADA demonstrates that Dr. Kieffer’s lab successfully incorporated these gene edits into human islets derived from human embryotic stem cells. When the cells were put into a petri dish with other immune cells, they survived the immune response that kills un-modified islets. This approach needs to be tested in an animal model before moving to human trials.

Updates on Vertex’s stem cell therapy, Zimislecel (VX-880)

Dr. Michael Rickels (Pennsylvania) presented on Zimislecel (VX-880) – a stem cell-derived islet therapy that requires immunosuppression, which is infused into a vein in the liver in people with T1D who have impaired hypoglycemic awareness and severe hypoglycemic events.

The phase 1/2 clinical trial, which is part of the ongoing pivotal phase 1/2/3 FORWARD-101 trial, is complete. Twelve participants received a single infusion of a full dose of cells and were followed for at least one year.

All 12 participants achieved the primary endpoint, which was elimination of severe hypoglycemic events and HbA1c levels less than 7%. 10/12 (83%) participants are insulin independent.

All 12 participants demonstrated sustained insulin production as measured by C-peptide, reduced external insulin therapy use, and achieved greater than 70% time in range. Mild to moderate adverse events were consistent with the immunosuppression regimen, infusion procedure, and complications from T1D.

These data were published in the New England Journal of Medicine and represent further evidence of the curative potential of manufactured islet transplantation for T1D. Breakthrough T1D’s support for Doug Melton, Ph.D.—whose proprietary lab-created islets are now being advanced by Vertex—goes back decades, both via research grants and an investment from the T1D Fund: A Breakthrough T1D Venture.

Read more about Vertex updates: https://breakthrought1d.ca/exciting-updates-from-vertex-stem-cell-based-therapy-clinical-trials/

6-month update on Sana Biotechnology’s immune-evasive islets

Dr. Per-Ola Carlsson (Sweden) presented data from Sana’s donor-derived islet therapy engineered with hypoimmune (HIP) technology showing that the cells can evade the immune system without immunosuppression. These cells were implanted intramuscularly in a first-in-human study into a person with T1D with no measurable insulin production.

Six months post-transplant, this person is consistently making their own insulin, as measured by C-peptide levels. A Mixed Meal Tolerance Test (MMTT) confirmed that these cells are not only surviving but also responding to changes in blood glucose levels. The person still requires external insulin therapy because they received a smaller dose of cells than the dose that would be required to achieve insulin independence. They did not experience any serious side effects, so the cells and procedure appear to be safe and well-tolerated.

This is a promising first step toward a functional cure for T1D that does not require immunosuppression. Sana Biotechnology is planning on applying this technology to manufactured islets. Sana has received support from the T1D Fund to advance their HIP technology in islets, and Breakthrough T1D continues to work closely with them.

Read more about Sana here: https://breakthrought1d.ca/cell-therapy-first-transplanted-islets-working-without-immunosuppressives/

Key Takeaways

Cell therapies are making significant headway in clinical trials, and some people receiving stem cell-derived islets become insulin independent. Researchers are tackling the biggest challenges for optimizing islet transplantation, including large-scale manufacturing, ensuring cell survival, and preventing detection by the immune system.

Updates on disease-modifying therapies

Dr. Heather Denroche (Integrated Nanotherapeutics) presented work on their lipid nanoparticle approach that can deliver antigen-specific immune therapy for T1D. This is done with a combination “vaccine-like” product that uses their proprietary multi-cargo lipid nanoparticles platform to co-deliver mRNA expressing certain islet-proteins (to enable antigen-specificity) and small molecule immunomodulators (to switch off the harmful autoimmune attack on islets). They have demonstrated that this therapy prevents and reverses diabetes in mice, which warrants further preclinical development as a promising treatment for T1D.

Laura Sanz Villanueva (Australia), who works in the lab of Breakthrough T1D-funded researcher Dr. Thomas Kay presented on a mechanistic follow-up study to the BANDIT clinical trial. The Breakthrough T1D-funded phase 2 BANDIT study in Australia showed that baricitinib, a JAK1/2 inhibitor that prevents immune cell communication, can increase insulin production as measured by C-peptide in people with recently diagnosed T1D. The present study found that baricitinib can reduce the number of natural killer (NK) cells in the pancreas, which are involved in the autoimmune destruction of beta cells. This data provides valuable insight into the mechanism of baricitinib-mediated protection of beta cells.

Key takeaways

Research that tackles a variety of approaches to disease-modifying therapies is showing true promise and potential to offer medications that will make T1D management easier and safer.

Updates on improving lives research

Adjunct-to-Insulin Therapies

There was significant focus on GLP-1 receptor agonists (GLP-1RAs) and SGLT inhibitors (SGLTi) in reducing long-term complications and improving glycemic control in people with T1D.

GLP-1 receptor agonists

Glucagon-like peptide 1 receptor agonists mimic the hormone GLP-1, which elevates insulin and regulates appetite. Examples include Ozempic® (semaglutide) and Mounjaro® (tirzepatide), which acts on both GLP-1 and a similar target, GIP.

SGLT inhibitors

Sodium-glucose cotransporter inhibitors target kidney cells to prevent them from reabsorbing glucose into the blood so it gets excreted as waste. Examples include Farxiga® (dapagliflozin) and Zynquista® (sotagliflozin).

Dr. David Cherney (Toronto) presented a review of SGLTi and GLP-1RAs in reducing chronic kidney disease (CKD) in T1D:

  • In the EMPA-KIDNEY trial, empagliflozin (SGLTi) improved kidney health in people with T1D.
  • In the  ATTEMPT trial funded by Breakthrough T1D Canada and CIHR, dapagliflozin (SGLTi) improved time in range (TIR), reduced HbA1c levels, and had positive effects on kidneys in youth with T1D.
  • The Breakthrough T1D-funded enrolling phase 3 SUGARNSALT trial is testing whether sotagliflozin (SGLTi) can prevent progression of moderate to severe kidney disease in people with T1D, and it includes careful diabetic ketoacidosis (DKA) risk mitigation strategies.
  • The Breakthrough T1D-funded phase 2 REMODEL-T1D trial is testing if semaglutide (GLP-1RA) can improve kidney health in people with T1D.

Key takeaways

Breakthrough T1D is working toward a future where these drugs are an option for people with T1D to better manage their blood glucose levels and reduce the potential of long-term complications.

Canadian data was presented from the Breakthrough T1D-funded BETTER Registry which showed that of nearly 1,400 adults with T1D, approximately 14% (n=192) were using an adjunctive therapy. Amongst this group, the most common was Metformin (39% of the 192 adjunct therapy users), followed by GLP-1RAs (27%), SGLTi (21%), and a combination of these (13%).

While these therapies are not approved for use in adults with T1D in Canada, the Diabetes Canada Clinical Practice Guidelines were updated at the beginning of 2025 and are in the first in the world to recommend considering the (off-label) use of adjunct therapies for selected adults with T1D to help them meet their treatment goals.

Updates on diabetes device research

Dr. Alanna Weisman (Toronto) presented a review of barriers and enablers to diabetes technology in people with T1D. Across over 200 studies, the most common barriers included: racial or ethnic minority status, insurance concerns (e.g., coverage), and clinic- and provider-related factors (e.g., gatekeeping of information and/or prescriptions). The most common enablers included: patient education, patient support, and provider education. Dr. Weisman’s Breakthrough T1D-funded work is looking at barriers to technology use in socially disadvantaged Canadians.

Teams led by Dr. Anne-Sophie Brazeau and Dr. Rémi Rabasa-Lhoret (Montreal), who oversee the BETTER Registry, presented the following data from the Canadian registry on device use:

A comparison of technology use in adults over the age of 50 years of age from the BETTER Registry data (n=674), showed similar rates of insulin pump use in adults with T1D in their 50s (39%) and 60s (38%), but this was slightly lower for adults above the age of 70 (35%). More pronounced was the difference in rates of CGM use in adults in their 50s and 60s (85% for both groups) compared to the much lower rate in adults above the age of 70 (73%).

The BETTER Registry also has a significant wealth of patient-reported outcome measures that inform us of factors such as fear of hypoglycemia. In a sample of 115 adults with T1D, the introduction of automated insulin delivery (AID) reduced the number of hypoglycemia instances reported monthly, the number of nighttime symptomatic hypos, and perhaps most importantly, the average fear of hypoglycemia based on validated survey measurements. These findings support the potential of AID to reduce the burden of hypoglycemia in adults living with T1D.

Key takeaways

Breakthrough T1D-funded research into device access and development of next gen diabetes devices will enable improved daily management and reduce some of the mental and emotional burden of living with T1D.

To watch a video recap: https://www.breakthrought1d.org/news-and-updates/everything-you-need-to-know-about-ada-2025/ 

ADHD and type 1 diabetes collide

Guest post:
Mark E. Paull, CME,
Substack: adhd-t1dm.substack.com,
Published Writer | Lived-Experience Advocate | Type 1 diabetes since 1967 |

This is my experience. It may apply to others—perhaps we all share certain aspects of it—or it may not. The connections between ADHD, cognition, and perception need more research. What follows is not a claim, just the reality as I live it.

The Relentless Dance

When I was eleven, a doctor looked me in the eye and said:

“You won’t live past thirty-five.”

He didn’t say it cruelly. It wasn’t meant to be a punishment or a scare tactic. It was clinical, matter-of-fact, as if he were giving me a weather forecast. I remember the sterile smell of his office, the crisp white of his coat, the way my mother gripped my hand just a little tighter.

Type 1 diabetes took over my life—numbers, syringes, and survival became my world. The carefree days of schoolyard games and comic books faded into one relentless focus: control.

But no one saw the real threat: ADHD.

I just didn’t know it yet.

At eleven, I was impulsive, forgetful—constantly losing things, losing track of conversations. My mind bounced from thought to thought, never settling. No one thought much of it. I was the ‘daydreamer,’ the ‘bright but careless’ kid—energetic and scattered. No one thought much of it.

But diabetes doesn’t care if you forget, if you get distracted, or if your brain works differently.

ADHD thrives on chaos, distraction, and forgetting things that could kill you. But diabetes? It demands precision, structure, and unwavering consistency.

And so, my life became a war between two disorders that should never have existed in the same body.

The first time I forgot to take my insulin I was at school.

It was lunchtime. My tray had exactly 60 grams of carbohydrates—a number drilled into my brain through endless diabetes training. Math was now a part of eating. I knew the steps: Take the insulin shot first, then eat. Simple.

Except, before I could inject, someone at the next table cracked a joke.

I turned to laugh.

And in that instant, my attention jumped tracks.

By the time I remembered my insulin, my blood sugar was already climbing. My head felt heavy, my body sluggish, my thoughts wrapped in cotton. I stumbled through the rest of the day, my hands shaky, my brain slow, the numbers on my meter confirming what I already knew—I had lost control. Again.

But the worst moments weren’t when I forgot my insulin.

They were when I wasn’t sure if I had taken it already.

At night, I’d lie in bed, staring at the ceiling.

Did I take my long-acting insulin? Or did I just think about taking it?

If I took it twice, I could die in my sleep.

If I didn’t take it at all, I could wake up in a coma.

I’d get out of bed, check my blood sugar, and stare at the number on the meter—except that wasn’t an answer. It was a riddle. My ADHD brain had no reliable memory for something so repetitive. If I had taken my insulin fifteen minutes ago, would my blood sugar even reflect it yet?

I couldn’t trust my brain. I couldn’t trust my body. And I was completely alone in figuring out how to navigate a world where I was both my own lifeline and my own worst enemy.

Everyone thought diabetes would be my biggest challenge. But the real fight? My mind.

Managing diabetes means following the same steps every day, without fail:

  • Check blood sugar before eating.
  • Calculate insulin dose with perfect accuracy.
  • Eat at the right times—not too early, not too late.
  • Carry emergency sugar at all times.
  • Double-check. Triple-check. Never miss a step.

No room for error. But ADHD turns routines into chaos.

I created systems—alarms, notes, even tying my insulin pen to my lunchbox—all to help me remember.

But ADHD has its own logic.

I’d hear the alarm and immediately forget why I set it.

I’d see a note and think, I’ll do that in a minute, and then never do it.

I lost count of how many times I ignored the insulin pen, too distracted by whatever was happening in my head.

Some days, I was hyper-focused on managing my blood sugar like a scientist, tracking every fluctuation, analyzing trends, predicting outcomes. I was in control.

Other days, I’d get so absorbed in writing, reading, or just daydreaming that I wouldn’t eat until I was shaking and drenched in sweat. I was out of control.

There was no in-between.

And the worst part? My brain played tricks on me.

On a school field trip, I packed my insulin in a zippered pouch, zipped it into my backpack, and congratulated myself.

Halfway through the trip, I realized I had no memory of actually taking the shot.

I froze on the bus, trying to replay the morning in my mind.

Had I unzipped the pouch?

Had I pulled out the pen?

Had I done the injection?

My brain said I had. My gut said I hadn’t. I had to guess.

That was ADHD and diabetes in a nutshell. A daily roulette of whether my own memory could be trusted.

And the world—my doctors, my teachers, even my parents—didn’t understand.

They saw a kid who “just needed to be more responsible.”

I saw a kid fighting a battle that no one had prepared him for.

No one warned me that ADHD and diabetes played by opposite rules.

No one had told me I would have to figure this out alone.

The Systems That Failed Me

Diabetes is a disease of routines. ADHD is a disorder of breaking them.

That’s the contradiction I lived with every single day.

Diabetes means doing the same steps, in the same order, every single time:

  • Check blood sugar.
  • Calculate insulin dose.
  • Inject insulin.
  • Eat at the right time.
  • Adjust for exercise, stress, or anything unpredictable.
  • Carry emergency sugar.

If you mess up, you don’t just feel off—you crash. Your blood sugar spikes too high or drops too low, and both can kill you.

ADHD means you can know all of this and still forget in the moment. It means routines don’t feel natural. It means every time you try to build a habit, it crumbles under the weight of distraction, impulsivity, forgetfulness, or just your own unpredictable brain.

So I tried to outsmart myself.

I followed all the advice, experimented, and adjusted. Nothing worked.

The Alarm System That Never Worked

Doctors said: ‘Set alarms.’ So, I did—alarms for insulin, meals, blood sugar checks. They didn’t work.

ADHD made my brain filter alarms as background noise. I would hear it, register that it was important, and then—just as quickly—forget about it. Or worse, I would turn it off thinking, I’ll do it in a second, and then never do it.

Sometimes, I would snooze the alarm so many times that by the time I actually paid attention, it was hours too late to take my insulin.

Other times, I would check my blood sugar, see a number in range, and think, I must have already done it. But had I? I had no way of knowing. One of the worst times was during an exam in high school. I had set a quiet vibration alarm on my watch to remind me to take my insulin at lunchtime.

But I was so deep in concentration that I just ignored it.

Two hours late. Blood sugar climbing. My brain drowning in syrup. The test became a blur.

My body was sluggish, my mind dull, my focus shot.

I stumbled through the rest of the test, barely able to think straight.

That was the moment I realized: even alarms don’t work if your brain doesn’t register them as urgent.

The Notebook That Disappeared

Since alarms didn’t work, I switched to writing things down. A doctor suggested a logbook, so I bought one that made me feel responsible.

Every entry was supposed to be neatly recorded—time, dose, blood sugar, carbs eaten.

It was a foolproof system.

Except ADHD means nothing stays where you put it.

I lost that notebook within the week. The next one disappeared too.

Eventually, my room became a graveyard of half-filled diabetes logs, scattered across drawers and bookshelves, each one abandoned because I had forgotten where I left it.

One time, I found an old logbook and thought, Great, I’ll start using this one again!

Only to realize all the entries were from two months earlier.

The worst part? Even when I did manage to write things down, I’d forget to check what I had written.

I had all the information—I just never looked at it.

The Trick That Didn’t Work

Next strategy: leaving things in obvious places.

  • I put my insulin pen next to my toothbrush so I’d see it every morning.
  • I left glucose tablets by my bed for nighttime lows.
  • I even put sticky notes on my laptop saying, CHECK BLOOD SUGAR NOW.

But ADHD doesn’t work like that.

I saw those things so often that my brain stopped noticing them.

The sticky notes became part of the scenery.

The insulin pen next to my toothbrush? I brushed my teeth, stepped over it, and walked away.

The glucose tablets? Completely ignored until I needed them in a panic.

Nothing worked. No matter how hard I tried, no matter how many systems I built, my brain refused to cooperate.

The System That Finally Helped (Sort of)

“It took years, but I realized I had to work with my brain, not against it.”

Instead of trying to force myself into a rigid structure, I worked with my brain’s natural tendencies.

  • Blood sugar checks happened when I took off my shoes.
  • Habit stacking – I tied diabetes tasks to things I already did without thinking.
  • Morning insulin was paired with coffee.
  • Timers, not alarms – Instead of setting a one-time alarm, I used countdown timers.
  • “Take insulin in 10 minutes” became a more immediate task than a random beep.

 Tech helped – When continuous glucose monitors (CGMs) became available, they changed everything.

Now, my phone told me when I was high or low, rather than relying on me to remember.

It wasn’t perfect, but it was better than anything else I had tried.

Still, the frustration remained:

Why did I have to work twice as hard just to stay alive?

Every missed dose, every forgotten blood sugar check, every time I had to scramble to correct a mistake—it wasn’t carelessness.

It wasn’t irresponsibility.

It was ADHD.

And no one had ever told me how much harder that would make managing diabetes.

For years, I thought ADHD only made my diabetes worse. That it was just another obstacle, another failure waiting to happen. But I was wrong.

ADHD and Hyperfocus: The Unexpected Lifesaver

For years, I thought ADHD made me bad at diabetes. I was wrong. It made me survive it.

The same brain that forgot insulin could also hyperfocus on it.

On good days, I tracked my blood sugar with an obsessive precision that rivaled medical professionals. I could see patterns before my doctor did.

I would run my own experiments—how different foods affected my glucose, how stress changed my numbers, how exercise played into everything. When my brain locked in, I became my own best endocrinologist.

One time, my doctor raised an eyebrow at my self-made spreadsheet, color-coded and filled with notes about insulin absorption times.

“You track this better than half my patients,” he said.

I smirked. Of course I did. It was an ADHD deep-dive.

Pattern Recognition and Instincts

I began to trust something most people didn’t even think about—my gut.

ADHD made me notice tiny details, subtle shifts. I could feel a low blood sugar coming before the numbers confirmed it. I sensed when something was “off” before I could logically explain why.

It wasn’t magic—it was pattern recognition, honed from years of analyzing every mistake, every reaction, every small variable.

Doctors told me, “You can’t feel a blood sugar drop before your CGM does.”

But I could. And I did. Repeatedly.

Crisis Mode: When ADHD Became a Superpower

ADHD brains are wired for high-pressure situations. When everything was going wrong, when my blood sugar was crashing, when I had seconds to act, my brain flipped into hyperfocus survival mode.

There was no hesitation. No distraction. Just clear, sharp action.

One night, I double-dosed insulin—again. I felt the symptoms creeping in fast. My heart was racing. My hands were shaking. The room tilted. I knew what was coming.

But instead of panicking, my brain locked in.

I lined up exactly what I needed: juice, glucose tablets, honey. I ran calculations in my head. I spaced out my carb intake strategically. I set timers to check my glucose every five minutes. I executed it like a pilot handling an emergency landing.

An hour later, I was stable.

This wasn’t luck. It was ADHD’s ability to hyperfocus under stress, to rapidly problem-solve, to process chaos in real time.

This happened again when I was traveling. I was in a new city, out of my usual routine, and my blood sugar started dropping rapidly. I had no glucose on me.

But instead of panicking, my brain did what it always does in a crisis—it calculated.

I spotted a small café down the street and sprinted in, gasping out, “Juice—fast.” The cashier blinked at me, confused. I didn’t have time to explain. I grabbed the nearest bottle of orange juice and chugged it at the counter, shaking hands gripping the plastic like a lifeline.

That’s what ADHD does.

It makes normal life hard—but when things go wrong? I thrive.

Reframing ADHD: A Strength, not a Weakness

For so long, ADHD felt like an enemy. It made diabetes harder. It made me fail. It made me feel reckless and irresponsible.

But then I saw the full picture: ADHD didn’t just create problems—it helped me solve them.

It made me notice details others missed.

It made me experiment and adapt faster than most people.

It let me hyperfocus on solutions when I needed them most.

It forced me to find creative workarounds when standard systems failed.

I was never going to be the patient who followed perfect routines. My brain wasn’t built for that. But I could be the patient who out-thought diabetes.

Who adapted faster.

Who found new ways to manage when the textbook ones didn’t work.

I stopped trying to fight my brain and started working with it.

That shift changed everything.

One of the biggest lessons I learned was that success didn’t have to look like “normal” success.”

For me, a “perfect” diabetes day wasn’t about hitting every number exactly right—it was about catching mistakes before they spiraled out of control.

It was about realizing my brain wasn’t broken—it was different.

Instead of beating myself up for not being consistent, I leaned into my strengths:

  • I used hyperfocus to analyze patterns and spot mistakes.
  • I stopped fighting alarms and started linking insulin to physical habits I already had.
  • I trusted my instincts when my body told me something was wrong.

For years, I thought I was just bad at diabetes.

That I was irresponsible, careless, lazy.

I wasn’t.

I was managing two conditions that fundamentally clashed with each other.

And I was doing it without any guidance, without understanding why my brain worked the way it did.

The First Time I Gave myself Grace

I remember the exact moment I stopped being angry at myself.

It was late at night.

My blood sugar was dropping, and I was sitting on my bed, glucose tabs in one hand, phone in the other, staring at an article about ADHD and diabetes.

It described everything I had been through—forgetting insulin, missing doses, panicking over double-dosing, the exhaustion of trying to be “good” at diabetes but never quite getting there.

I’d been told I was bad at diabetes. For so long, I believed it.

Now I see—it was never a fair fight.

And I had never been failing.

I felt like I was reading my own life story.

For the first time, I didn’t feel like a failure.

I felt seen.

I was never alone.

It was my brain.

And my brain wasn’t broken.

It was just different.

What I Wish Someone Had Told Me Sooner

If I could go back and talk to my eleven-year-old self sitting in that doctor’s office, I would tell him this:

“Dear 11-year-old me: You are not failing. The world just doesn’t understand how your brain works—yet. You are not lazy. Your brain works differently, and that’s okay. Diabetes will be harder for you than it is for some people, but that doesn’t mean you’re failing. You will find ways to adapt. They won’t always be conventional, but they will work for you. You will mess up. It’s not your fault. It’s part of learning how to manage two conditions that weren’t designed to play nicely together. You will survive this.”

No one told me those things when I was younger.

So I’m telling them to myself now.

What Success Looks Like for Me Now

For years, I measured success by how well I could imitate neurotypical diabetes management.

Now, I measure success differently:

1. Did I catch a mistake before it became dangerous? That’s a win.

2. Did I problem-solve creatively when my brain wouldn’t cooperate? That’s a win.

3. Did I show myself patience instead of self-hatred? That’s a win.

Success isn’t perfection. It’s about figuring out how to live.

Speaking to Others Like Me

I know I’m not alone in this.

There are others out there—kids, teens, adults—trying to manage diabetes with a brain that doesn’t follow the rules.

To them, I say this:

Your ADHD isn’t a curse. It isn’t a weakness. It’s a challenge, yes, but it’s also a tool.

You can survive this. You can thrive. You can find ways to make it work.

For years, I thought I was fighting myself.

Now, I see I was fighting a battle I was never meant to fight alone.

ADHD and diabetes together are hard.

But I am not failing.

I was never failing.

I was surviving.

The doctor was wrong. He didn’t know my fight. I didn’t just survive—I thrived. And that? That’s everything.

Breakthrough T1D Walk a success coast to coast

Throughout June, thousands of supporters in nearly 50 communities gathered across the country to raise funds for type 1 diabetes (T1D) research.

Breakthrough T1D Walk (formerly the JDRF Walk to Cure Diabetes) is the largest fundraising event in Canada that unites the T1D community who are dedicated to making every day better for the estimated 300,000 Canadians living with type 1 diabetes (T1D), as we drive toward curing this disease. Breakthrough T1D Walk has raised more than $143 million to date in its over 30-year history, making it one of the longest running and most successful fundraising events in the country.

The collective fundraising goal is $3.2 million that will help support Breakthrough T1D Canada’s mission to find cures for T1D, and to date more than $2.5 M has already been raised through 1312 teams, 9112 participants and 17807 donations!

Additional Walks took place in May with several communities still planning Walks in the Fall, including schools participating as part of our Breakthrough T1D School Walk Program, where schools across the country can host Walks supported by their students and teachers throughout the year.

This year has truly been a national effort with Walks taking place in every province, from Newfoundland to Vancouver Island, and even with Walk Your Way events happening in Yukon and Nunavut.

The Walk is so much more than just a fundraiser. It’s a chance for families living with T1D to meet, share their stories, and gain support from each other. Many Walks had a tent for newly-diagnosed families, manned by volunteers who have lived through a T1D diagnosis and were available to offer support, resources, and encouragement. 

There were exciting kids’ games, activities from our corporate sponsors, Star Wars characters, amazing custom-made Team t-shirts, face-painting, and so much more! Each Walk location had their own unique offerings to make the day one to remember for all the participants.

At the Breakthrough T1D Walk in Toronto, we were once again joined by Breakthrough T1D ambassador Max Domi. Max met with families, took hundreds of selfies with fans, signed countless autographs and shared a bit of his T1D story from the stage, especially noting the role his parents played (who were both in attendance) in helping him learn to manage his T1D and help smooth his path to the NHL. As always, Max was generous, welcoming and brought hope and inspiration to attendees, particularly our newly-diagnosed families.

We want to thank our Walk Ambassadors who are helping to break the stigma of living with T1D, paving the way for a new generation of younger people living with T1D who are fiercely proud and committed to making life better today while we work towards a tomorrow free from T1D. They are so inspiring, and we thank each of them for their efforts and enthusiasm.

Thank you as well to our corporate partners, whose support helps us to build a special day of community spirit, along with important resources for T1D families, particularly those new to T1D.

Thank you to our amazing and tireless Breakthrough T1D Volunteer Committees and our staff who spend months working to ensure that the Walks run smoothly and that our participants have the best possible experience.

Our Breakthrough T1D Walks simply couldn’t happen without our incredible Walkers, volunteers, donors, vendors, and our local, regional, and national partners. Truly, we can’t do it without you.

Together we walked, knowing that with each step we got closer to the finish line – a world free from T1D. And we won’t stop until we cross it.

Breakthrough T1D-funded clinical trial of adjunct-to-insulin therapy for T1D teens publishes results

Dapagliflozin, an SGLT2i medication often used for people with type 2 diabetes, showed improved kidney function and glycemic management in teens with type 1 diabetes. This trial supports a growing body of evidence that supports the use of adjunctive therapies (drugs beyond insulin) for T1D.

Adolescence can be a challenging time to manage type 1 diabetes (T1D). Life (and hormones!) change in all sorts of ways, and many teenagers experience higher than recommended blood glucose levels as a result, which can mean an increased risk of complications later in life. The study of novel therapies that can improve glycemic control in teens with T1D and reduce the risk of diabetes complications is critical to improving the lives of youth living with diabetes.

Adjunct-to-insulin therapy – i.e., taking another drug alongside usual insulin treatment – is one approach that could help on both fronts. For example, sodium-glucose cotransporter-2 (SGLT2) inhibitors are a class of oral medications approved for type 2 diabetes that reduce glucose from the blood from being absorbed by the kidneys, instead encouraging glucose to be released in urine. Dr. Farid Mahmud and his team at the Hospital for Sick Children (SickKids) in Toronto conducted a clinical trial that tested the safety and efficacy of an SGLT2 inhibitor called dapagliflozin in teens with T1D. The ATTEMPT trial (Adolescent Type 1 Diabetes Treatment with SGLT2i for Hyperglycemia & Hyperfiltration) was funded as part of the Breakthrough T1D – CIHR Partnership to Defeat Diabetes.

The ATTEMPT study

The ATTEMPT trial aimed to determine the safety and effectiveness of an SGLT2 inhibitor called dapagliflozin on managing blood glucose and on improving kidney function in adolescents aged 12 to 18 with T1D. The study had two main goals:

  1. To determine how effective dapagliflozin would be at improving kidney function and glycemic management; and
  2. To determine if the drug increased the risk of diabetic ketoacidosis (DKA) and if additional safety measures could mitigate any increased risk  

ATTEMPT was led by Dr. Farid Mahmud, an endocrinologist and researcher at The Hospital for Sick Children in Toronto.

A total of 98 participants and their families attended 5 in-person visits over 22 weeks and were given a random assignment to the dapagliflozin group, or the placebo group (a small pill that contains no active medicine). During the study, participants kept taking insulin, wore a continuous glucose monitor (CGM), tested for blood ketones, and were to report any adverse events. Over 850 potential participants were approached over the course of 2-years to take part in the study.

Results:

ATTEMPT is the first of its kind, landmark trial designed to evaluate the effectiveness of SGLT2 inhibitors to optimize diabetes control and prevent early subclinical kidney complications in an at-risk pediatric population with T1D.

Efficacy:

The study showed that a low dose of SGLT2 inhibitor could safely be given to youths and adolescents to improve kidney function as well as improve glycemic management. There was a clinically significant decline in HbA1c of 0.47% in the treatment group as well as a 9% increase in average time in range from CGM metrics. There was no change in the total daily insulin dose.

Safety:

The trial was designed with strict safety protocols to mitigate the risk of diabetic ketoacidosis. In collaboration with patient-partners (those living with and caregivers of individuals with T1D) a DKA Risk Mitigation Strategy was employed due to the increased risk of DKA during euglycemia (normal range glucose levels). The protocol included routine ketone monitoring with guidance for action above the threshold of 0.6 mmol/L.

Dapagliflozin was well tolerated with no study-related serious adverse events. There were no significant differences in the proportion of participants who experienced elevated ketone levels, hypoglycemia and genitourinary tract infections in the Dapagliflozin vs Placebo groups. A single case (N=1) of mild DKA was seen in the Dapagliflozin group. While rates of DKA were low, a greater number of elevated blood ketone events ≥0.6mmol/L were seen in the Dapagliflozin group (n=106) vs Placebo group (n=62) (P<0.001), demonstrating the importance of the patient-centered DKA Risk Mitigation Education strategy operationalized during the study.

The results from ATTEMPT will hopefully pave the way for further research and longer studies on the potential benefits of using adjunctive therapies to help manage type 1 diabetes.

Please note that dapagliflozin, or any SGLT2 inhibitors are not approved for individuals with T1D by Health Canada.

Mahmud, F.H., Bjornstad, P., Clarson, C. et al. Adjunct-to-insulin therapy using SGLT2 inhibitors in youth with type 1 diabetes: a randomized controlled trial. Nat Med (2025). https://doi.org/10.1038/s41591-025-03723-6

Clinical trial participation is crucial for moving forward vital T1D research from the lab to the people who need it most. To find T1D trials that are recruiting participants, and if you qualify, please visit: clinicaltrials.breakthroughT1D.ca.

Cell therapy first: transplanted islets working without immunosuppressives

On Jan 7, 2025 (Sweden)Sana Biotechnology released significant clinical data: the first person with type 1 diabetes (T1D) who received deceased donor islets engineered to evade the immune system is producing insulin without immunosuppression.

UPDATE: June 23, 2025
Sana Biotechnology presented updated data on June 23, 2025 at the six-month follow up timepoint. The single patient dosed with hypoimmune donor islets continues to produce insulin in response to a mixed meal tolerance test (MMTT) without the use of immunosuppressants. 

The details

This is a big step for cell-based therapies for potentially curing T1D. Sana’s first-in-human study consists of allogeneic islets, meaning they are derived from an external source, which in this case is the pancreases of deceased donors. These islets were engineered to avoid recognition by the immune system (hypoimmune) and were implanted intramuscularly into a person with T1D. After four weeks, circulating C-peptide increased, meaning that the beta cells are alive, healthy, and producing insulin—all without the need for immunosuppression and no safety issue. This is the first evidence of engineered islets successfully avoiding immune destruction.

What this means for the T1D community

While this is an incredibly promising step forward for the T1D community, to have allogenic cells survive without the use of immunosuppressants, this trial relied on deceased donor cells, of which there will never be enough to provide to everyone living with T1D.  The trial was done in a single participant and is reporting only 4-weeks of data – this is a proof-of-concept study that is promising but very preliminary.

What’s next: lots to look forward to

Breakthrough T1D believes that the best chance for T1D cures lies in stem cell-based therapies since deceased donor islets are in short supply, while stem cell-derived islets can be produced at scale. Engineering cells to evade immune attack is a new path forward to protect the insulin-producing beta cells and avoid the use of immunosuppressants. Most importantly, this technology is being studied to apply to stem cell-based therapies, which is a scalable solution for many more people with T1D. This hypoimmune technology moves us closer to the possibility of having enough immune-evading cells for everyone with T1D.

Another trial is in progress testing a similar approach (CRISPR) in Canada – https://clinicaltrials.breakthrought1d.ca/clinical-trial/NCT05565248

While this approach will take significant time, effort, and money, every day we take another step toward a possible life-changing T1D cure. 

Breakthrough T1D’s Role

The primary objective of Breakthrough T1D’s beta cell replacement efforts is to place insulin-producing cells into people with T1D without the use of immunosuppressants. Breakthrough T1D strongly supports the development of stem cell-based therapies that do not require broad immunosuppression and Breakthrough T1D International based out of the US recently launched an initiative to accelerate this faster than ever (Project ACT – Accelerate Cell Therapies). To contribute to the advancement of these game-changing therapies, the T1D Fund: A Breakthrough T1D Venture invested in Sana recognizing that their hypoimmune engineering technology held significant promise for T1D cell therapies. We look forward to seeing how the trial progresses.

Kendra Fisher: being open about the emotional challenges of caregiving for a child with type 1 diabetes

Kendra Fisher is a former member of Team Canada’s hockey program, a 3x world inline hockey champion, and a firefighter. She is also the Founder of Mentally Fit; a professional speaker, a mental health coach, and an author in the making. Kendra may be best known for her hockey career, and for making the life-altering decision to step away from her dream of playing for Team Canada in order to manage diagnoses of Generalized Anxiety Disorder, Panic Disorder, Clinical Depression, Agoraphobia, and OCD.

Kendra has been open about her journey with mental illness, and deeply vulnerable in sharing the devastating loss of her son, River, at 32 weeks gestation. When her son Bodhi was a toddler, he was diagnosed with type 1 diabetes (T1D). Now a Breakthrough T1D Canada Ambassador, Kendra is also involved with the Breakthrough T1D Walk in Toronto. She recently sat down with Breakthrough T1D Canada to share how her family navigated Bodhi’s diagnosis, all in the wake of infant loss and during the challenges of the pandemic.

Breakthrough T1D Canada: Can you share a little about the time of Bodhi’s diagnosis?

Kendra:

It was during COVID, so everything already felt intense and overwhelming. I was working as a full-time firefighter, on shift in a high-stress environment. Fortunately, Bodhi’s other mom, Kristy, was incredibly intuitive and picked up early signs that something wasn’t right.

Bodhi had been drinking constantly; he’d go from glass to glass, drinking everyone’s water. At first, we didn’t think too much of it. On its own, the thirst didn’t seem alarming. But at the same time, he was soaking through diapers. We started doubling up, laying down crib liners, trying everything, and nothing worked.

Kristy kept raising concerns that this was something more serious. Having lost our son, I was sure we were being hypervigilant—looking for problems, being too cautious. But one morning, Bodhi decided he was only going to use the potty, and by 11 a.m., he’d filled it ten times. Kristy messaged me as I was coming off shift and said she was taking him to the urgent care clinic at St. Joe’s.

Just based on those two symptoms, they checked his blood sugar, and it was incredibly high. We were told he was likely in DKA and that we either needed to admit him immediately or take him by ambulance to Sick Kids to begin treatment.

Because of COVID protocols, only one parent could go into the hospital. Kristy went in with him while I waited outside. I’ll never forget that call, Kristy was crying. She told me the doctor was coming to meet me in the lobby to give permission for me to come in. That’s where I was told, face to face, “He has diabetes.” Sick Kids would be overseeing his care.

The surreal part was that those were the only symptoms; excessive thirst and urination. He was otherwise his normal, happy, outgoing self. They got him on an IV right away and started titrating insulin. It was all happening so fast, trying to understand what was going on while still in complete shock.

They later got a more precise ketone reading and, miraculously, Bodhi wasn’t in full DKA. They called him a “warrior.” He had somehow drunk enough water to flush out the ketones. At 6 p.m. that same day, they told us we could take him home.

As a firefighter, my only experience with diabetes was responding to people in crisis. From that limited perspective, it didn’t seem possible that it was safe to bring him home. But that was day one of our new life.

And we were navigating all of this in isolation. One parent at appointments. We’d just lost River. We had our older son, Finley, who was five at the time, and the last time we had gone to the hospital for his baby brother, we came home alone. His fear was enormous. He was terrified for his little brother. As a family, we had to divide and conquer. Bodhi went straight into diabetes day care at Sick Kids the next day, and we were thrown into this world we didn’t yet understand.

Breakthrough T1D Canada: What do you want other parents to understand about type 1 diabetes?

Kendra:

I truly believe people mean well when they share their responses to learning about Bodhi; they want to help, be kind, and be supportive. But a lot of people confuse type 1 diabetes with type 2 diabetes. We were met with well-meaning, but misinformed advice. People telling us Bodhi would be fine if we cut out sugar or junk food. A friend giving him an apple instead of a lollipop, not realizing I hadn’t accounted for it in his insulin dose and that it didn’t matter that it was a healthy snack.

Others suggested things like a keto diet so he wouldn’t need insulin. And while these suggestions might come from a good place, they can be exhausting to correct, especially when you’re still trying to understand it all yourself.

Even those with experience of T1D can sometimes overwhelm you with too much information. In the beginning, it felt like there was no soft place to land. No clear starting point. This diagnosis doesn’t just affect your child; it affects your whole family.

Finley has been an incredible big brother. He’s patient, kind, and understanding. We went from having an open snack shelf to locking cupboards. His eating schedule has had to adapt to Bodhi’s. But it’s hard, finding balance between giving your child with T1D the attention they need, while still being fully present for your other child.

Breakthrough T1D Canada: What have you learned since those early days?

Kendra:

I’ve learned how important it is not to lean too heavily into toxic positivity. At first, I tried to “silver lining” everything. “At least we have CGMs, pumps, amazing doctors.” And it’s all true. But I also needed to leave room for honesty.

Through the lens of mental health, I’ve learned that it’s okay to say, “This sucks sometimes.” Bodhi doesn’t always want the attention that comes with being different; asking a parent to enter carbs when a friend offers a snack or navigating insulin doses at events. That constant spotlight can be hard for a kid.

And as a parent, it’s heartbreaking knowing there are parts of his experience I’ll never truly understand. But we sit with him. We let him tell us when it’s hard, when it hurts, when he’s frustrated. We don’t try to fix it, we just let him know it’s okay to feel that way.

In the beginning, I didn’t want to accept what it really meant to be his caregiver. The decision fatigue is real. Constant calculations: Is it hot out? How active will he be? What’s the carb ratio? When’s the next blood sugar spike? What’s the correction factor? These aren’t questions other parents have to ask themselves before heading out the door.

We give Bodhi permission to feel everything. To be disappointed. To be sad. We don’t downplay his experience. That’s not our right. And it wouldn’t help him feel any less alone.

Breakthrough T1D Canada: Any final thoughts you’d like to share?

Kendra:

We are so grateful for the research, the tech, and the medical teams that support us. These things do make managing T1D more possible than ever before.

But we take it one day at a time, with honesty.

(Somewhere in the conversation, Kendra receives a message from Bodhi’s kindergarten teacher.)

Kendra:

I saw the message and my heart jumped. It turned out another child had hit Bodhi on the shoulder. The teacher was just letting me know and had informed the other parents too. I took a breath and reminded myself, he’s upright, he’s okay, we’re winning today.

That’s how we do this.

One breath at a time.

One moment at a time.

You can learn more about Kendra Fisher and follow her podcast here: https://kendrafisher.com/

Accelerating Cures: Four New Grants from the Breakthrough T1D – SCN Partnership

We’ve made major progress in the development of cell replacement therapies for type 1 diabetes (T1D) over the past few decades – much of it right here in Canada. We know that manufactured islets can be safely implanted into people, where they start to make insulin. But there is more work to do to advance these therapies to bring them to more people with T1D.

To drive new work in this area, Breakthrough T1D is pleased to announce a partnership with Canada’s Stem Cell Network (SCN), a non-profit, federally funded organization focused on stem cell and regenerative medicine research. Together, Breakthrough T1D and SCN will support four new projects led by Canadian researchers.

This announcement is an exciting expansion of a strategic partnership that began in 2021. In line with both organizations’ commitment to training future research leaders, we worked together to establish the J. Andrew McKee Fellowship program, awarded annually to a postdoctoral researcher working in regenerative medicine to join the Breakthrough T1D Centre of Excellence at UBC. Past fellows (awarded in 2022, 2023 and 2024) have brought expertise from many fields and countries to the Centre’s research team.  Additionally, with both organizations’ interest in accelerating research to commercialization, Breakthrough T1D collaborated with Stem Cell Network to pilot a training program that aimed to increase the regulatory literacy of research trainees, which has subsequently reached many trainees working in regenerative medicine across the country.

To continue the increasing momentum in the field of stem cell-based therapies for T1D, we have now expanded our partnership to fund new translational research focused on innovation and commercialization. We are now excited to be able to announce four jointly funded projects that will receive support from May 2025 – April 2027. These grants are part of SCN’s 2025 national competition on regenerative medicine which is supporting a total of 36 grants.

Dr. Tim Kieffer (UBC), Dr. James Shapiro (University of Alberta), Dr. Takanori Takebe (Cincinnati Children’s Hospital), & Lunar Therapeutics (Vancouver, BC) Fueling Biotechnology Partnerships Award

Combining stem cell-derived islets and vasculature for a better islet replacement product

Current cell therapies for T1D (i.e., islet transplantation), while often effective, are hampered by reliance upon donated organs and poor cell survival after transplant, necessitating large doses of cells and repeat procedures.  This ambitious new project will address both the source of islet cells and the low cell survival rates associated with islet transplantation by accelerating Lunar Therapeutics’ pre-clinical development of a stem cell-derived islet replacement product, what Takebe’s lab describes as ‘complex miniature organs’ for T1D.

This product will consist not only of insulin-producing cells, but also endothelial cells – like those that line blood vessels and the heart. Endothelial cells will support islet cell survival and engraftment upon transplantation.

To accomplish this objective, Lunar Therapeutics will bring together Canadian expertise in stem cell-derived islets and clinical islet transplantation led by Drs. Timothy Kieffer and James Shapiro. The team will also include US-based Dr. Takanori Takebe who specializes in designing complex organoids composed of various cell types. Using technologies developed across each member’s laboratory, this multidisciplinary team will work to deliver an effective islet cell replacement solution.

Dr. Marya Ahmed & Dr. James Shapiro (University of Alberta) – Impact Award

Using naturally derived gels to optimize cryopreservation (extreme cold storage) of stem cell-derived islet

 The implantation of stem cell-derived islets in people with T1D can restore insulin production, eliminating the need to inject insulin and improving the life quality of patients. However; after islet cells are harvested (from cadaveric donors) or created (from engineered stem cells) they must be stored before being used to treat a person with T1D. Currently, the storage and transportation of islet cells is difficult and the only storage method is freezing at low temperatures in the presence of reagents (chemical solutions) that help with the freezing process. However, these reagents cause cell death during thawing and can also cause allergic reactions in people when transplanted. 

This project will address this gap in the field by aiming to develop non-toxic, naturally derived gels to optimize stem cell and islet freezing and storage. The identified gel-based products will be evaluated for commercial scale production. The success of this project will provide new intellectual property that will be of interest to researchers and companies in regenerative medicine in Canada and across the globe.

Dr. Corinne Hoesli (McGill), Dr. André Bégin-Drolet (Laval), Dr. Richard Leask (McGill), Dr. Andras Nagy (Sinai Health, Toronto), Dr. Steven Paraskevas (McGill) – Impact Award

Vascular lattice bioartificial pancreas for diabetes cellular therapy
(Using blood vessels to create a better encapsulation device for islet replacement therapies)

Stem cell-derived islets offer a potentially unlimited source of islets for transplantation. Since stem cell-derived islets carry unique risks compared with donor-derived islets, containment within a device could allow retrieval if off-target growth ever occurs. However, encapsulation devices that have been tested in clinical trials so far and have shown minimal success, mainly because blood supply to the cells is limited within the devices. In this project, the team proposes to develop a device where the stem cell-derived islets are placed around pre-established vessels that can improve islet cell survival and speed of insulin responses via improved blood supply. In this project, they will optimize their device design and conduct advanced preclinical studies.

This project could lead to better survival and function of stem cell-derived islets. The device could provide long-term blood glucose control without external intervention. The project can also pave the way for other engineered human-scale bioartificial organs.

Dr. Megan Levings, Dr. Bruce Verchere, Dr. Francis Lynn & Dr. Peter Zandstra (UBC) – Impact Award

Using stem cells to create a human T1D immune system model in a petri dish

There are many new treatments on the horizon for T1D, such as replacement of insulin-producing cells, and therapies that seek to block autoimmunity, such as so-called “inverse vaccines” and immune cell therapies. However, a major barrier to all these therapies is the lack of an easy-to-use model in which their effects on human cells can be tested before advancing to human trials. The standard pre-clinical model is to test therapies in small animal models of T1D, but this has significant limitations since it is nearly impossible to replicate the human immune system. In fact, diabetes has been ‘cured’ hundreds of times in a mouse model, which has not translated to humans.

To overcome this barrier, Dr. Levings and her team will establish a new a model that recreates human T1D autoimmunity in the lab. The model will use stem cells to create the three types of cells that are involved in the disease: insulin-producing cells and two different types of immune cells, known as T cells and antigen presenting cells. Using the model, cells can then be combined in different ways to create a method that resembles what usually happens during autoimmunity.

A model of human T1D that can be generated in the lab will help test potential treatments and prompt new questions about why T1D develops, and how to prevent it. Thus, this research has the potential to support the further development of innovative therapies that may offer new approaches to prevent or treat people with T1D.

Curing T1D is the north star of Breakthrough T1D, and we are thrilled to continue to build upon and strengthen the relationship with SCN towards our shared goal of a world free from T1D through innovation and forward-thinking research.

Breakthrough T1D Canada will continue to provide updates on these projects as they become available.

Jim Beatty – navigating an adult diagnosis in the spotlight

Jim Beatty is a passionate volunteer in the fight against type 1 diabetes.  For many years, Jim has volunteered with the JDRF, and now Breakthrough T1D, emceeing events and participating on various committees.

Jim has been living with type 1 diabetes for more than 20 years, following his adult diagnosis. Jim is a former journalist who now operates his own communications company in Victoria, B.C., where he likes to hike, fish and enjoy the West Coast with his family.

Breakthrough T1D Canada: Can you share what you remember about the lead up to you being diagnosed?

Jim Beatty: I was healthy, active; I had two young kids. At the time, I was the bureau chief for the Vancouver Sun covering the provincial legislature, which was a busy, stressful job. Every fall, I had my bloodwork done trying to get my cholesterol down. In the fall, everything was fine with my bloodwork. But things would soon change. As Christmas approached, I know exactly the morning – I was going to interview the Premier (Gordon Campbell at the time) for the usual year-end discussion, where we talk about the year that was, and year that will be, a kind of a state of the union address.
 
I remember I got dressed at home, put on my suit and tie but then saying to my wife that I don’t feel good, I don’t think I can go to work. I was so sick, and it hit me so fast that my wife had to call the press secretary to cancel the interview for me.

For two weeks, I had what I thought was very severe flu. But two months later, I noticed I was always exhausted, I would fall asleep after dinner, and I had an unquenchable thirst. I started needing to wake up in the middle of the night to use the bathroom. On their own, all these symptoms are all pretty benign and easily ignored or explained away.

But it wasn’t getting better, so I went to my family doctor, and he said let’s just do some bloodwork. Bloodwork came back and the doctor, said “you have diabetes.” Not type 1, just ‘diabetes’. I knew nothing about diabetes. Type 1 or two. Nobody had it in my family, I had no familiarity with this disease, and back then, there was no Google to look anything up.

I had an initial misdiagnosis of type 2, because when you were my age (36), for most doctors, they see it as most likely being type 2. I was told to modify my diet and do more exercise. I did all that, even though I had already been living that way before for the most part. I got my blood tested again and the A1C was still really high. They put me on Metformin, and that didn’t work either. And so, I needed to go insulin, with multiple daily injections. 

I didn’t like needles, and I remember sitting on the side of my bed, with an actual needle and having to put that in my belly. I will never forget how tough that was, how invasive it felt. February was when I first told I had diabetes, and by summer I was on insulin therapy.

Breakthrough T1D Canada: How did you navigate your diagnosis?

Jim Beatty: I did everything the doctors told me to do; I didn’t foot drag on that. But I did feel robbed; I did feel that it might be a mistake (the diagnosis of T1D). I did think maybe I could exercise or diet my way out of it, maybe it’s a blip, a false-positive? I was doubting and I had persistent thoughts that I could work my way out of it. But after a while, it was quite clear it wasn’t going anywhere.

Unfortunately, I didn’t have anyone to talk to about it. I didn’t know anyone with type 1. Other than my family doctor, who I saw every 3-4 months, I was navigating it on my own. I wish that the supports that are available today were available then, especially for adults.

It was isolating, lonely, and there were just so many questions. Things that I take for granted now, I had no idea then. It was all new. I’d never handled a needle before. I’d never done finger poking (to check blood glucose levels). I certainly didn’t know what basal and bolus meant (types of insulins). My endocrinologist was talking in terms and language that I had no reference for. It was a confusing and frustrating period.

Initially, I was a newspaper reporter, and I did share with the two colleagues who I worked closely with, they needed to know I had this condition, that I might need sugar, that I was having frequent doctor’s appointments. I didn’t let management or bosses know, however. My thought process was that it was going to be an impediment to my career success, that it would be seen as a weakness, or a vulnerability. And that it might be a reason not to promote me to the next level.

Not long after my diagnosis, I moved to television broadcasting. I was the Bureau Chief with CTV Vancouver. I did tell the cameraman who I was working with every day, because for example if I told him I need to eat, I needed to eat. It wasn’t just hunger. It was a need.

But I still wasn’t comfortable with my diagnosis, and I didn’t speak freely, outside of family and friends.

I had moved my job again and I was the chief news anchor for CHEK News in Victoria, and this philosophy still hadn’t changed much. Bosses, news director, management – none of them knew I had type 1. I largely kept my diagnosis invisible. I would be anchoring the news, and when we went to commercial break, I had a little table next to me, and I would do a finger poke to see if I needed sugar, or to calibrate my insulin. And people didn’t know I was doing this; it was all hidden.

Then, a call from Breakthrough T1D (then JDRF), would change everything. I was asked to emcee a fundraising gala event. They were asking because I was a broadcaster and was known in the community, but they had no idea I had T1D. The request threw me into a bit of a tailspin because I knew if I was going to be genuine and host a fundraiser for type 1 diabetes research; it would be disingenuous not to admit I was also living with this.

I thought about the request for a few days. I ruminated over whether I should ‘go public’ and eventually I decided that yes, I’m going to do it. The first people I spoke with were my bosses. I said, ‘look I’m going to be hosting this event on Saturday, and it could be a news story when I reveal that I also have type 1 diabetes.’

Then, I stood up on the stage, and I basically ‘came out’ – ‘I am not just your emcee, I am one of you.’ And I told my story. It was a great night. It was a very liberating evening. People came up to thank me, I immediately felt support. And it was the beginning of being open about living with this disease and living with it as you need to. Unafraid to talk about it, being honest about any assistance you might need. It was a pivotal moment because it freed me.

I had no connection with Breakthrough T1D (JDRF) before that event, and it started a relationship that continues to this day. Galas in Victoria, Vancouver, Walks, Rides, government relations committee. It was very liberating and took me places I didn’t expect.

Breakthrough T1D Canada: What would a cure look like for you?

Jim Beatty: What I think of as a cure is something that will return my life to normalcy. Living without having to carry snacks with me, being hooked up 24/7 to the devices, being able to go for a walk or a hike, or to eat pizza, and not doing all the thinking and calculating that comes with it. A cure would be a life when I no longer have to constantly think about diabetes and all its complications.  It would be a return to having the life I had before. So, yes, of course, it would be fantastic.

Five years, five years, every diabetic has said that they’ve been hearing ‘the cure is coming in five years’ for decades. That ‘five years’ is a false hope, so I don’t say that anymore, or believe it could be possible in five years.

So, when I think about the cure, I don’t think about the ‘cure’ per se. I am more interested in treatments today that are making my life better. And there are so many that I am using today that were pipe dreams twenty years ago. I am living my life better today because of the advancements in treatment, and those incremental things have made a significant difference. Today my A1C levels are better than they’ve ever been in my life, and that is because of the CGM and insulin pump, and how they help me manage my (blood glucose) levels more precisely.

A cure is a far-off, long-distance notion to me. I view treatments as real, closer, and more tangible.

Breakthrough T1D Canada: Is there anything else you’d like to share with the T1D community?

Jim Beatty: The thing I wish I had done was to be more open to these discussions, open about my diagnosis, earlier and not keep it a secret. By holding onto it, holding onto this big secret of something so significant in my life – at the time I thought it was the right thing. But now I know that’s not the case. I could have learned more, had more support, my journey would have been better and easier, much sooner.

So please know that you don’t need to feel isolated. You can be open; you can reach out for assistance. Take the help. And know that life is good today. 

Exciting New Grants in the Breakthrough T1D Cures Portfolio

We are pleased to announce 6 new grants funded via Breakthrough T1D International (USA) to stellar Canadian scientists.  These grants all support cell therapy research to replace insulin-producing cells in people living with T1D.

Dr. Cristina Nostro, University Health Network (Toronto)

Manufacturing clinical-grade stem cell-derived islets – 2 Grants

To date, global efforts on this work – largely led by Canadians – has used research-grade cell lines which are less expensive and more readily available for experimentation. To move these therapies towards the clinic there is a requirement for Good Manufacturing Practices (GMP) to be met. This includes properly trained personnel, GMP-certified premises and equipment, clinical-grade starting cell lines, validated protocols and practices, etc. 

Two shots on goal: These two grants will each use Dr. Nostro’s world-renowned differentiation protocol to engineer islets using clinical-grade stem cell lines in GMP-certified facilities that have the ability to scale up the differentiation process.

Consider Dr. Nostro’s differentiation protocol as an excellent sourdough bread recipe perfected in her kitchen with consistent, delicious results. That recipe will now be taken to two different commercial bakeries to use their ingredients and facilities to see if they can make the same excellent sourdough loaves consistently in large production quantities.

Dr. Guy Rutter, CHUM Montreal

Imaging to explore the survival and function of stem cell-derived islets transplanted in mice

Goal: A novel imaging technique to examine human stem cell-derived islets in mice

  • Will allow real-time comparison of transplant sites (liver vs under skin)
  • Better assessment of cell death / blood supply / immune attack

A significant hurdle for assessing T1D and islet transplantation is that there is virtually no way to ‘see’ islets inside a person, even in small animals. No imaging technique allows us to ‘look at islets’ and see how many are alive, functional, producing insulin, etc.  This is why some clinical trials using islet transplantation devices (microencapsulation) have involved device removal at periodic timepoints so that the islets can be removed from the body and examined to evaluate their survival and function. Dr. Rutter is proposing a novel imaging technique to ‘see’ islet functioning in mice, which can help guide factors affecting the survival and function of transplanted islets.

Dr. Patrick MacDonald, University of Alberta

Artificial Intelligence (AI)-driven benchmarking for understanding and improving stem cell-derived islets

Over the past 5+ years, Dr. MacDonald and his team have created a groundbreaking database: humanislets.com, which isolates islets from donated pancreases (from deceased donors with T1D, T2D, and without diabetes) and characterizes the islets and their function using “omics”. This is a broad term to encompass the study of all the biological molecules of a cell, such as genomics (DNA), transcriptomics (RNA), proteomics (proteins), and metabolomics (metabolites), etc. Together “omics” data creates an exceptionally robust characterization of each islet – and all of this is made publicly available to scientists around the world through this research.

Goal: Dr. MacDonald’s new grant will expand this Breakthrough T1D-funded database to include stem cell-derived islets for comparison to donor islets and incorporate artificial intelligence methods to dig deeper into this comparison.

Dr. Haoning Cen, University of British Columbia

Postdoctoral Fellowship (Supervisors: Dr. Francis Lynn & Dr. Leonard Foster)

A blueprint for making better beta cells

Goal: to create blueprints for donor beta cells vs stem cell-derived beta cells

  • Will use protein detection to identify 10,000+ proteins
  • Will classify each protein’s quantity and location to compare ‘natural’ vs stem cell-derived beta cells

Dr. Sean Kinney, University of Toronto

Postdoctoral Fellowship (Supervisor: Dr. Michael Sefton)

Biomaterial platform for islet transplantation under the skin

Goal: to create a biological scaffold (a small structure made from bio-compatible materials that can support new cell growth and survival) for islet transplantation using regenerative hydrogel.

  • The scaffold will support blood vessel, nerve, tissue growth to support islet survival
  • Immunomodulating therapy (modifying the immune system’s function, for example) embedded in the scaffold will be explored

Faces of the $100M Campaign to Accelerate: Aryssah’s story

Type 1 in year 1: turning the page on an unexpected diagnosis at university

Meet Aryssah, an incredibly resilient adult living with type 1 diabetes (T1D). She is a committed $100M Campaign to Accelerate volunteer and champion of diabetes and mental health support. She devotes her time to appreciating the incredible philanthropic donors who help fuel Breakthrough T1D’s Mental Health Strategy for Type 1 Diabetes. She also generously funds a scholarship for students with T1D attending their first year of university.

This Mental Health Awareness Month, Aryssah candidly shares her T1D journey to spread awareness of the daily burdens endured by those living with this autoimmune disease. Her story paints a stark picture of the gaps in diabetes care and support in Canada, particularly for newly diagnosed adults—gaps we are working to address with donor support.

Nearly 300,000 Canadians live with T1D today, with approximately 12,200 diagnoses anticipated in 2025 alone. $100M Campaign to Accelerate donors play a significant role in speeding up a future where everyone with T1D has access to the care, tools, and resources they need to thrive.

Had Aryssah received comprehensive support at diagnosis—addressing not only the physical demands of T1D but its mental tolls, too—her early years with T1D may have looked different. But like many impacted by T1D, Aryssah does not let her diagnosis, or this disease, stop her from courageously pursuing a hopeful and fulfilling life. Aryssah shares her story with candour and the utmost care for the T1D community, hoping to garner even more support to improve lives and accelerate cures.

When Aryssah was 19, she became lethargic and would get foot cramps after sports, which was unusual for a young varsity athlete. With additional symptoms like increased thirst and significant weight loss, she was diagnosed with T1D shortly after a visit to her family doctor.

Had she been diagnosed just one year prior, she would have gotten support and resources through the pediatric diabetes clinic. Instead, she was treated like an adult and had to figure out how to manage this autoimmune disease on her own. She remembers going to the diabetic nurse’s office only to be given a couple of insulin pens and have them prick her finger. “It felt very independent,” she says, “in reflection now, part of me is a little sad for myself at that time, because if I was diagnosed a couple of months earlier, I would have been set up at SickKids and would have been walked through the whole process with my mom.”

Initially, Aryssah didn’t feel that T1D was too severe. As an active young adult, she felt invincible. She even ran a marathon just a mere three months after being diagnosed. But for the first few years living with T1D, she struggled to navigate her new reality. She found it challenging to balance such a complex disease while attending classes, competing as an athlete, and wanting to participate in the entire university experience.

Ill-equipped to properly manage her blood glucose levels, she was in and out of the hospital throughout school and, as a result, unable to finish her fourth year. These hospitalizations were very traumatic for her, and overall, she didn’t feel like herself.

“I did not take care of myself in the way that I should have. And it’s probably because I didn’t have that support in the beginning to set me up for success down the road,” she says.

In her mid-twenties, she sought out a psychotherapist to figure out how to deal with these traumas and the mental health aspects of living with T1D. Therapy allowed her to process and accept her diagnosis and has been integral to her health journey ever since. Perseverance and optimism are in her nature, and she has always used her diagnosis as fuel to combat adversity.

Later in life, when Aryssah could better manage her blood sugars, she returned to school and completed her university degree with Honours. For all those living with T1D or newly diagnosed, she advises, “This is one instance of your health where you have to relinquish control almost automatically because you can do everything right (you can track your carbs and can inject what you need to), and your blood sugar’s still going to muck up; it’s not a science…We are all trying our best and are so much larger than our actual diagnosis or disease.”

Through Breakthrough T1D, Aryssah also developed meaningful connections with the T1D community. Having support from those who understand the disease firsthand has been invaluable to her. As a form of giving back, Aryssah established the Torchbearer Scholarship for Type Ones to help support others navigating the highs and lows of T1D while attending university. All students who live with T1D entering their first year of university are invited to apply for this $1,000 scholarship opportunity. The application deadline is July 31, 2025, at 11:59 p.m. EST.  

“You cannot see the destruction that diabetes does to your brain as a young adult or even as you continue to grow,” Aryssah says, “and that is sometimes even more important than blood sugar management because it goes hand-in-hand. Mental health is something that we need to take into consideration. It never really comes up with diabetes.”

$100M Campaign to Accelerate donors are speeding up progress to ensure that no one is left to manage this disease alone, as Aryssah and countless others have had to.

Outstanding philanthropists are advancing our Mental Health Strategy, supporting vital initiatives like the Mental Health + Diabetes Training Program and Directory, community mental health grants, research interventions, and peer-support programs. These leadership gifts ($5,000 or more) help fill critical gaps in T1D care, improve health outcomes, and combat stigma.

To make a meaningful investment through the $100M Campaign to Accelerate and become part of our exceptional major gift community, please contact:

Kim Lacombe 
Vice President, Philanthropy
klacombe@breakthroughT1D.ca
438-814-1668

Peter Dreimanis: In his own words

Peter Dreimanis is a multidisciplinary artist, perhaps best known as a co-founder of the Juno Award-winning band July Talk.

In June 2020, he was diagnosed with type 1 diabetes (T1D) as an adult and had to learn to navigate the disease against the backdrop of lockdowns and uncertainty of the pandemic.

Peter was part of the Beyond the Numbers: Real stories of navigating mental health and T1D video series project, that captures real stories from people living with this disease, exploring how T1D affects their mental health and emotional well-being.

Peter recently sat down with Breakthrough T1D Canada to share his story of being diagnosed later in life, and how T1D has changed his life as an artist, partner and father.

Breakthrough T1D Canada: Tell us a little about when you were diagnosed.

Peter: Well, I got COVID at the very beginning of the pandemic. We’d been touring as a band for the better part of 12 years or so, and I was never someone to listen to my body. I didn’t have the skills to know what my body needed, to determine if something was wrong. I was better at silencing things – driving through pain, ignoring the signals to slow down etc.

A while before the pandemic shutdown, in January of 2020, my partner bought tickets to see my favourite team play in Buffalo. We went across the border and when we came home, we got incredibly sick, worse than I have ever been. It was an extreme illness. You know what a flu bug feels like, but I wasn’t plugged into the scientific news, wasn’t paying attention to the slowly emerging news about covid. So, all this to say, I got very sick for a couple weeks, and then slowly we approached the shutdown.

Around April, I started having people say I ‘looked great’, I looked like ‘I had been working out, lost weight’ – and I didn’t know what to make of it. One of my roommates was vegan, I’d been eating those meals, not going out for food, but I wasn’t really making lifestyle choices.

And always, I continued to just push through. I didn’t pay it much thought until around May/June – I was experiencing extreme thirst, I was eating ice cream, eating giant meals of sourdough bread and rice, and still I was losing weight.

I attributed it to being a workaholic in a state struggling to accept that we had to slow down. We (July Talk) had been working on an album. I was in denial, and still just trying to make the album work.

And I continued to worsen, I would have days where I would be drinking 10-12 litres of water a day, I couldn’t get enough. I would walk up the stairs with equipment and think I would pass out. We did huge shows in summer 2020, we put together a socially distanced concert experience, drive-in and broadcast at the drive in. It was a massive undertaking; I worked full-time for 3 months to try and figure out how to pull it off. So, I was laser focused on that. And I remember I would go down for a nap at like 6pm, so exhausted I couldn’t think, and I wouldn’t wake up until the next morning. I was just so exhausted, so thirsty, so confused.

And yet – it wasn’t until a professional photographer took some photos to help promote the show that I realized, wow, I look really skinny. I weighed myself and I was 50lbs lighter. My partner had been on me about how thin I was looking. You could see my ribs. I had no frame of reference; I had never been rewarded for slowing down. But thank goodness I went and got blood tests and was immediately diagnosed – first with type 2.

I was initially put on metformin, and it obviously didn’t work. I fortunately was seen by an endocrinologist who immediately recognized it as type 1. So, I went on insulin therapy, and I still see this same endo today. I was connected with a DEC (diabetes education coordinator), and a nurse. I was weeks away from this show. They warned me that if I didn’t take this on (managing my T1D), I could die. My partner was and has been incredible, And I realize now how much T1D affects the people who love you. I harbour some shame and guilt around my will to take it on; for not truly recognizing, or perhaps accepting, the severity of the situation.

I did my first insulin shot two or three days before we went on stage, and I really didn’t know what I was doing. I was using fingerpricks (to measure blood glucose levels) at the time. I wasn’t taking it seriously right away. It’s truly a continuous lifestyle change, and I don’t think I really understood the gravity of that yet. I got through the shows somehow without going low. My adrenaline seems to send me up. In my experience touring since diagnosis, I always have juice on stage. I’m always going on stage at around 9 (blood glucose level) – my adrenaline has the opposite effect. So, when the adrenaline crashes, that’s when I need the fast-acting carbs.

As soon as this show was done, I went north of the city (Toronto), turned off my emails and phone, did Zoom calls and really started to learn what it means to live with type 1 diabetes.


Breakthrough T1D Canada: How have you adapted since then to your new normal with T1D?

Peter: I felt so supported. I was totally floored by the system that springs into action, I would have rather it be in person instead of over Zoom etc., but it was absolutely stunning how quickly they were able to get us up to speed. Once I was ready, I made every effort to learn how to carb count, etc., – I had notebooks full of stuff. It really takes a while to learn. I liken it to when you’re a new driver and the insurance company tells you that you ‘will get in an accident’. My T1D ‘accident’ was that I had a low (hypoglycemic episode) that resulted in a grand mal seizure, and it was just miscounting my carbs, there was more learning to do. I didn’t know then what I know now.

When it happened, I was on a long phone call with my parents, and I started feeling sweaty and shaky. By the time I was trying to get juice, I was reading at 2.4 (a very low blood glucose level). And by then it was too late, and I went into seizure.

It was a horrifically traumatic experience for me and my family. For a while after, I had panic around lows. I definitely accepted going higher for about a year after that, because of how scary that experience was. I felt like a ticking time bomb that could explode at any minute. All you have to do is look into your partner’s eyes to know how scary it was for them. But knowing that danger gave me a better understanding of what the body experiences when it goes low, and what it actually means to live with this chronic condition. I can handle a low now. But it took time to have the clarity to understand it wasn’t going to be like this forever. And I had some consequences from that episode, like not being able to drive for six months, losing trust in my body etc. But I see it now as a profound life experience, and I grew up a lot.

To speak more about the balance of it, and this is something I give a lot of thought to, we are all simply by waking up in the morning, we are all in a place of trusting our bodies to function as we think they should do. Our bodies are one of the most complex systems in existence, and the pancreas producing insulin, and all the rest of our parts doing what they should do – we never truly think about it. It’s an incredible privilege, the way we think we’re going to be okay is by believing we will be OK.

And for those of us with T1D, that might take technologies, or therapy or whatever you need to rebuild that trust. We have a contract with our bodies, and sometimes I think about it, like when we’re running down a street, there are moments when we’re airborne. And we trust that we’ll land. And I think about how to keep that trust and cultivate that trust in your body. Because it’s the only way we can get through life. And now as someone with T1D, I need to spend more time building that trust because it’s the only way to be OK.

Breakthrough T1D Canada: What T1D research excites you the most right now?

Peter: I don’t consider myself a fully informed person on T1D research, but I’ve read about smart insulins that might eliminate carb counting, and this intrigues me. To free myself of that constant testing (blood glucose levels), to no longer live in a world where you must understand everything you’re eating, to be precise about insulin against that. In a restaurant it’s a guessing game (how many carbs are in a meal). Life doesn’t work that way, in exacts. When you live an untraditional lifestyle, I’m not in a 9-5 job, I’m a parent, sometimes I want to eat my kids’ leftovers without having to calculate percentages.

I say godspeed to the researchers who might be able to eliminate the 10K thoughts I have in a day. Not thinking that much, that would be freedom that I can’t comprehend, and I think especially about people who have lived with T1D for most of their life. It would be incredible. I eagerly await this. I feel very grateful for my CGM and insulin pump, and in all honesty, they drive me nuts, a lot of the time I hate it, but also feel lucky in that I have only experienced T1D when this tech exists, in this unbelievably progressive time. I don’t take that for granted at all. I feel lucky in that way.

Breakthrough T1D Canada: Do you have any last thoughts to share with your fellow T1D community?

Peter: Having the opportunity to hear other people share so openly and honestly as part of the Beyond the Numbers video project turned out to be more helpful than I could have realized before we started.

Talking with others is so therapeutic, none of us are perfect, and we will have many hard and challenging days and times living with T1D. I encourage people to be kind to themselves, to share as much as they are comfortable when things are hard, and to reach out for support when it’s needed. It’s a journey, and there will be bumps along the path, but the support is there.

Follow Peter on IG both at @peter_dreams and @julytalk

Donate | Donnez